Video

MF Progression to Acute Myeloid Leukemia and Subsequent Treatment

Author(s):

Ruben Mesa, M.D.,Rami S. Komrokji, M.D.

Before closing out their program on myeloproliferative neoplasms, Rami Komrokji, MD, and Ruben Mesa, MD, discuss the potential for progression of MF to acute myeloid leukemia and highlight key treatment strategies.

Related Videos
A panel of 3 experts on CML
Related Content
Image of red blood cells.
October 3rd 2024

Education on MPN Symptoms, Treatments Leads to Greater Involvement in Care

Darlene Dobkowski, MA
An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Illustration of blood cells.
September 17th 2024

Vonjo Improves Thrombocytopenia, Anemia in Patients With Myelofibrosis

Jax DiEugenio
Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Illustration of myeloproliferative neoplasms, including essential thrombocythemia.
August 31st 2024

Essential Thrombocythemia Trial Launched Evaluating Bomedemstat

Alex Biese
The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy.
FDA approved
August 14th 2024

FDA Approves Niktimvo for Chronic GVHD

Brielle Benyon
Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.